Palivizumab

Type: Product
Name: Palivizumab
First reported Apr 13 2014 - Updated Apr 14 2014 - 1 reports

France moving ahead with biosmilar substitution

New legislation in France would allow retail pharmacists there to become the first in Europe to be able to supply patients with biosimilar versions of the biologic drug indicated on the prescription. The new rule, contained within Article 47 of this year’s ... [Published Pharma Times - Apr 13 2014]
First reported Apr 14 2014 - Updated Apr 14 2014 - 1 reports

Global Biosimilars (Recombinant Non-Glycosylated & Recombinant Glycosylated Proteins & Recombinant Peptides) Market 2013-2018

Research and Markets (http://www.researchandmarkets.com/research/8rhkdb/biosimilars) has announced the addition of the "" report to their offering. The global market is estimated to reach $2.0 billion by 2018 at a CAGR of more than 20% between 2013 and ... [Published Individual.com - Apr 14 2014]
First reported Apr 09 2014 - Updated Apr 09 2014 - 1 reports

Novavax appoints senior vice president of process development operations

Novavax, Inc., a clinical-stage biopharmaceutical company, has appointed Cynthia Oliver as senior vice president of process development operations. Dr Oliver will be responsible for all process development activities, with a specific focus on the company's ... [Published Individual.com - Apr 09 2014]
First reported Apr 08 2014 - Updated Apr 08 2014 - 1 reports

Competitor Analysis: Biosimilar and Biosuperior Therapeutic Antibodies

DUBLIN , Apr. 03, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/m5wnkh/competitor) has announced the addition of the " " report to their offering.(Logo:http://photos.prnewswire.com/prnh/20130307/600769)The present ... [Published Asian Hospital & Healthcare Management - Apr 08 2014]
First reported Apr 07 2014 - Updated Apr 08 2014 - 2 reports

Novavax: Promising Pipeline And Stable Revenue Add To Upside

SummaryNovavax has a strong clinical pipeline with multiple vaccines that have great potential. The company aims to establish approaches in order to better prepare for and more effectively respond to fast-spreading infections. Novavax's annual revenue ... [Published Seeking Alpha - Apr 08 2014]
First reported Apr 08 2014 - Updated Apr 08 2014 - 1 reports

In vivo potency of glycan variants of an RSV mAb [Immunology]

Andrew Hiatt a , Natasha Bohorova a , Ognian Bohorov a , Charles Goodman a , Do Kim a , Michael H. Pauly a , Jesus Velasco a , Kevin J. Whaley a , Pedro A. Piedra b , c , Brian E. Gilbert b , and Larry Zeitlin a , 1 a Mapp Biopharmaceutical, ... [Published PNAS - Apr 08 2014]
First reported Apr 01 2014 - Updated Apr 02 2014 - 1 reports

University of Maryland Unveils Master's Degree Program in Technology Entrepreneurship

/PRNewswire-USNewswire/ -- The University of Maryland , a national leader in entrepreneurship education and venture creation, today announces it will offer a new master's degree program in technology entrepreneurship starting this fall.The 30-credit, ... [Published OSIX News - Apr 01 2014]
First reported Mar 28 2014 - Updated Mar 28 2014 - 1 reports

3 Reasons to Buy Novavax, Inc.

The health care sector has fallen hard over the past month, and small caps in particular have led the sector lower. Because of the indiscriminate nature of this drop, I believe this rapid downturn could be creating some buying opportunities for investors ... [Published Motley Fool Discussion Boards - Mar 28 2014]
First reported Mar 25 2014 - Updated Mar 25 2014 - 1 reports

Discovery Labs Announces New Appointments to Management Team

/PRNewswire/ --Â Discovery Laboratories"Will has a track record of success in broad corporate, pipeline and product communications and investor relations, and brings significant experience in pediatric respiratory disease all valuable to coalesce our ... [Published BusinessWeek - Mar 25 2014]
First reported Mar 20 2014 - Updated Mar 20 2014 - 2 reports

AstraZeneca PLC : Annual Financial Report

ANNUAL FINANCIAL REPORTAstraZeneca PLC (the Company) announced today the publication of its Annual Report and Form 20-F Information 2013 (Annual Report); Notice of Annual General Meeting 2014 and Shareholders' Circular; a covering letter from the Chairman; ... [Published Investegate - Mar 20 2014]
First reported Mar 19 2014 - Updated Mar 19 2014 - 1 reports

BIOTRON : Patent Issued for Antiviral Compounds and Methods

By a News Reporter-Staff News Editor at AIDS Weekly -- Biotron Limited ( Sydney , AU) has been issued patent number 8669280, according to news reporting originating out of Alexandria, Virginia , by NewsRx editors (see also Biotron Limited ).The patent's ... [Published 4 Traders - Mar 19 2014]
First reported Feb 06 2014 - Updated Feb 06 2014 - 1 reports

Human medicines European public assessment report (EPAR): Synagis, palivizumab, Revision: 26, Authorised

Entities: Palivizumab

Quotes

...bring our RSV, seasonal influenza and pandemic influenza vaccine candidates to licensure," said Stan Erck, President and CEO of NovavaxNovavax Inc. "After working with us as a consultant for three years, I am delighted that Cindy has agreed to join Novavax to lead our process development efforts."
"The results represent a breakthrough and encourage us to move ahead with the RSV vaccine programs for the maternal immunization, pediatric and elderly indications in 2014" said Erck during the company's recent earnings call
...Novavax " approach to developing these and other, earlier-stage preclinical vaccine candidates, has tremendous commercial potential, and I am honored to lead the process development function that supports this exciting technology."
...Engineering's Maryland Technology Enterprise Institute (Mtech) , which is offering the master's program through the UMD Office of Extended Studies. "In addition to our most rigorous academic entrepreneurship track, for the first time, we are pairing this enriching academic experience with the skills and relationships of the university's acclaimed startup incubators."

More Content

All (20) | News (19) | Reports (0) | Blogs (1) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Global Biosimilars (Recombinant Non-Glycosylate... [Published Individual.com - Apr 14 2014]
France moving ahead with biosmilar substitution [Published Pharma Times - Apr 13 2014]
Novavax appoints senior vice president of proce... [Published Individual.com - Apr 09 2014]
HIV Monoclonal Antibodies: A New Opportunity to... [Published PLoS medicine - Apr 09 2014]
Competitor Analysis: Biosimilar and Biosuperior... [Published Asian Hospital & Healthcare Management - Apr 08 2014]
Novavax: Promising Pipeline And Stable Revenue ... [Published Seeking Alpha - Apr 08 2014]
In vivo potency of glycan variants of an RSV mA... [Published PNAS - Apr 08 2014]
Novavax : Appoints Dr. Cindy Oliver as Senior V... [Published 4 Traders - Apr 07 2014]
University of Maryland Unveils Master's Degree ... [Published OSIX News - Apr 01 2014]
Frederick County businesses reflect growth, pos... [Published Frederick News-Post - Mar 31 2014]
3 Reasons to Buy Novavax, Inc. [Published Motley Fool Discussion Boards - Mar 28 2014]
GenVec's CEO Discusses Q4 2013 Results - Earnin... [Published Seeking Alpha - Mar 28 2014]
Discovery Labs Announces New Appointments to Ma... [Published BusinessWeek - Mar 25 2014]
AstraZeneca PLC : Annual Financial Report [Published Investegate - Mar 20 2014]
Annual Financial Report [Published TrustNet - Mar 20 2014]
BIOTRON : Patent Issued for Antiviral Compounds... [Published 4 Traders - Mar 19 2014]
Novavax's CEO Discusses Q4 2013 Results - Earni... [Published Seeking Alpha - Mar 11 2014]
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - Feb 06 2014]
Medical Center Infusion Services Selected by RS... [Published PRWeb - Sep 27 2013]
Carbonic anhydrase IX (G250) anitbodies [Published PharmCast - Jul 04 2013]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - Feb 06 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.